Compare Bristol-Myers Squibb Co (BMY) vs Home Depot Inc (HD) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Home Depot (HD) trades at $343.06, up 1.77% on the day, with technical indicators showing bearish momentum despite recent price strength. The stock faces pressure from weakening big-ticket demand and margin compression, though Pro segment growth and housing market tailwinds provide support. Recent earnings show mixed results with Q2 2026 EPS expectations at $4.71. The company maintains strong profitability with 8.41% net margin and robust cash flow generation of $19.81B from operations in 2025.

HD presents a compelling long-term investment case with analyst consensus price target of $370.59 (8% upside) and 59% buy ratings, though near-term headwinds from rising mortgage rates and consumer spending caution warrant caution. The stock's current valuation at 23.99 P/E appears reasonable given strong ROE of 128.38% and consistent dividend payments, but investors should monitor housing market trends and competitive pressures in the home improvement sector.